Merlini L, Secondo V, Mammoliti S, Bellotti P, Castello C, Gallo L
Servizio di Oncologia Medica-E.O. Ospedali Galliera, Genova, Italy.
Anticancer Res. 1994 May-Jun;14(3B):1423-6.
We have evaluated the efficacy and toxicity of a chemotherapy consisting of methotrexate, mitoxantrone, 5-Fluorouracil and leucovorin in 21 advanced breast cancer patients. Among 20 evaluable patients, objective response was obtained in 6 patients (30%) with two complete responses, stable disease in 4 patients (20%), while 10 patients (50%) progressed. Median progression-free survival and survival were 10 and 15 months, respectively. The most frequently observed side-effects were myelosuppression and emesis; one patient, who had previously received doxorubicin at the maximum dose-limiting cardiac toxicity, died of congestive heart failure after the third cycle. This treatment is moderately effective for advanced breast cancer patients.
我们评估了由甲氨蝶呤、米托蒽醌、5-氟尿嘧啶和亚叶酸组成的化疗方案对21例晚期乳腺癌患者的疗效和毒性。在20例可评估的患者中，6例（30%）获得客观缓解，其中2例完全缓解，4例（20%）疾病稳定，而10例（50%）病情进展。无进展生存期和总生存期的中位数分别为10个月和15个月。最常观察到的副作用是骨髓抑制和呕吐；1例先前接受过最大剂量限制心脏毒性的阿霉素治疗的患者，在第三个周期后死于充血性心力衰竭。这种治疗对晚期乳腺癌患者有中等疗效。
